Evinacumab Reduces Lipids, Cholesterol in Hypercholsterolemia and Hypertriglyceridemia
Data from a meta-analysis of evinacumab trials reveal significant reductions in cholesterol and other lipid markers among patients with dyslipidemia.
Linkedin Muhammad Saqlain Mustafa Robert Rosenson Muhammad Saqlain Mustafa Aga Khan University Hospital Drug Administration Regeneron Pharmaceuticals Inc
Source: hcplive.com